Semaglutide cuts kidney risk in obesity

This publication has 25 references indexed in Scilit:

• 60th EASD Annual Meeting of the European Association for the Study of Diabetes
  Diabetologia, 2024
• Prevalence of Cardiovascular-Kidney-Metabolic Syndrome Stages in US Adults, 2011-2020
  JAMA, 2024
• Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
  Nature Medicine, 2024
• GLP-1 Agonists for Obesity—A New Recipe for Success?
  JAMA, 2024
• The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists
  Pharmacological Research, 2022
• Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial
  The Lancet Diabetes & Endocrinology, 2019
• Obesity
  Nature Reviews Disease Primers, 2017
• A systematic review and meta-analysis suggests obesity predicts onset of chronic kidney disease in the general population
  Kidney International, 2017
• Obesity-related glomerulopathy: clinical and pathologic characteristics and pathogenesis
  Nature Reviews Nephrology, 2016
• Fatty kidney: emerging role of ectopic lipid in obesity-related renal disease
  The Lancet Diabetes & Endocrinology, 2014